The human body's genetic code is a complex mechanism. As scientific research expands our understanding of genetics, there are therapies being developed that could offset the limitations associated with a defective gene.
Dr. Stephen Rose, Chief Research Officer at the Foundation Fighting Blindness, joins us on the line from Columbia, Maryland to discuss possible FDA approval for the treatment Luxturna. This could be the first approved gene therapy for retinal dystrophy.
This is the October 17, 2017 episode.
Keywords: gene therapy, Dr. Stephen Rose, chief research officer, Foundation Fighting Blindness, Dr. Steve Rose, Steve Rose, Dave Brown, FDA, Food and Drug Administration, Cellular Tissue and Gene Therapies Advisory Committee, Spark Therapeutics, voretigene neparvovec, Luxturna, RPE65 gene mutation , RPE65, gene mutation, retinal dystrophy, blind news, blindness, disability, medical, health, health news